Related Experiment Video
Updated: May 10, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous
Monica Verdoia1, Lucia Barbieri, Alon Schaffer
1Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della Carità", Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy, ve.monica@libero.it.
Insights
Platelet distribution width (PDW) does not increase the risk of periprocedural myocardial infarction (PMI) after percutaneous coronary interventions (PCI). This finding suggests PDW is not a reliable risk factor for thrombotic complications following coronary stenting.
Area of Science:
- Cardiology
- Hematology
- Interventional Cardiology
Background:
- Periprocedural myocardial infarction (PMI) is a complication of percutaneous coronary interventions (PCI), often linked to increased platelet activation.
- Platelet distribution width (PDW) may indicate platelet reactivity and morphologic changes, potentially influencing complications after coronary stenting.
Purpose of the Study:
- To investigate the relationship between platelet distribution width (PDW) and the occurrence of periprocedural myocardial infarction (PMI) in patients undergoing PCI.
- To determine if PDW is a predictive risk factor for PMI following coronary stenting procedures.
Main Methods:
- A study involving 1,300 consecutive patients undergoing PCI.
- Measurement of myonecrosis biomarkers (Troponin I, CKMB) post-PCI.
- Grouping patients based on PDW tertiles and analyzing associations with clinical factors and outcomes.
Main Results:
- Higher PDW was associated with older age, diabetes, prior cerebrovascular accidents, and specific medications (statins, ARBs, ASA, nitrates, calcium antagonists).
- PDW correlated with hemoglobin levels and inversely with platelet count and glycemia.
- Crucially, increased PDW was not found to elevate the risk of PMI or periprocedural myonecrosis, even in high-risk subgroups.
Conclusions:
- Platelet distribution width (PDW) is not associated with an increased risk of periprocedural myocardial infarction (PMI) in patients undergoing percutaneous coronary interventions (PCI).
- PDW should not be considered a risk factor for thrombotic complications after coronary stenting.
Abstract:
Periprocedural myocardial infarction (PMI) still occurs in a large amount of percutaneous coronary interventions (PCI), mainly due to increased platelet activation. Platelet size has been suggested as an indicator of enhanced reactivity and platelet distribution width (PDW) could reflect morphologic changes in platelets, therefore affecting their function and potentially increasing the risk of complications after coronary stenting. Aim of the present study was to evaluate the relationship between PDW and PMI. We included 1,300 consecutive patients undergoing PCI. Myonecrosis biomarkers were dosed at intervals from 6 to 48 h after PCI. Periprocedural myonecrosis was defined as troponin I increase by three times the ULN or by 50 % of an elevated baseline value, whereas PMI as CKMB increase by three times the ULN or 50 % of baseline. We grouped patients according to tertiles values of PDW (<12.1; ≥13.9). Higher PDW was associated with age (p = 0.03), diabetes (p < 0.001), previous cerebrovascular accidents (p = 0.04), therapy with statins (p = 0.001) and ARBs (p < 0.001), ASA (p = 0.02), nitrates (p = 0.006), calcium antagonists (p = 0.05) and lower pre-procedural clopidogrel bolus (p = 0.005). PDW related with haemoglobin levels (p < 0.001), while inversely to platelet count (p < 0.001) and glycaemia (p = 0.003). Patients with larger PDW had lower presence of coronary thrombus (p < 0.001), higher rate of coronary calcifications (p = 0.02), higher stenting rate (p = 0.03) and lower rate of distal embolization (p = 0.03). Larger PDW did not increase risk of PMI (p = 0.11; adjusted OR [95 % CI] = 0.94 [0.78-1.1], p = 0.55) or periprocedural myonecrosis (p = 0.73; adjusted OR [95 % CI] = 0.95 [0.82-1.1], p = 0.51). Results were confirmed even in higher-risk subgroups of patients. In patients undergoing coronary stenting, PDW does not increase the risk of periprocedural MI and therefore should not be considered a risk factor for thrombotic periprocedural complications after PCI.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiac Catheterization I: Pre-Procedure Overview
Peripheral Artery Disease III: Interprofessional Care
Cardiac Catheterization II: Right Heart Catheterization

